Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Women Underrepresented as Oncology Trial Corresponding Authors

Publish date:: October 10, 2019

Key clinical point: Female corresponding authors are underrepresented among phase 3 oncology trials in the research literature.

Major finding: Among the trials in the analysis, 17.9% had female corresponding authors.

Study details: The findings are based on analysis of 598 oncologic phase 3 RCTs that tested a therapeutic intervention and were published between 2003 and 2018.

Disclosures: The authors did not note any external funding and reported having no disclosures.

Citation:

Ludmir EB et al. JAMA Oncol. 2019 Aug 8. doi: 10.1001/jamaoncol.2019.2196.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Practice Management

Family planning issues loom large for female radiation oncologists,

Men occupy most leadership roles in medicine,

Video coaching may relieve anxiety and distress for long-distance cancer caregivers,

COVID-19 death rate was twice as high in cancer patients in NYC study,

More doctors used digital tools in 2019,